Clinical trial / 1995
Beta-carotene supplementation did not decrease and was associated with increased lung, prostate, and stomach cancers in male smokers.
In the ATBC Study, 29,133 male smokers aged 50-69 years were randomized to receive 20 mg beta-carotene, 50 mg alpha-tocopherol, both, or placebo daily for 5-8 years. Beta-carotene did not decrease cancer at major sites but showed higher cases of lung (474 vs 402), prostate (138 vs 112), and stomach cancer (70 vs 56). Vitamin E was associated with fewer prostate (99 vs 151) and colorectal cancers (68 vs 81), but more stomach cancers (70 vs 56). In contrast, higher baseline serum and dietary levels of both nutrients were associated with lower lung cancer rates.
- Study type
- 2 x 2 factorial, placebo-controlled, randomized intervention trial
- Who was studied
- 29,133 eligible male cigarette smokers aged 50-69 years
- What was measured
- Incidence of lung and other major cancers
THE PAPER
Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study.
Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK, Haapakoski J, Rautalahti M, Hartman AM, Palmgren J. Am J Clin Nutr, 1995.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.